(Total Views: 432)
Posted On: 04/06/2018 9:52:54 PM
Post# of 30015
Amarantus will have into July 2018 to complete an up-listing of the Amarantus common stock to a national stock exchange (the "Uplist" and further extend the moratorium. Upon the Uplist, there will be a further 9-month (until April 2019) moratorium on liquidating the securities issued in the Tender Exchange, followed by a highly restricted 'leak-out' arrangement that will significantly limit the Tender Exchange holders' ability to convert.
https://www.amarantus.com/news/press-releases...ate-update
GC has been delivering and hasn't changed or updated the timeframe...
1) Elto Pharma
2) MANF Therapeutic
3) Amarantus intends to assign these diagnostic assets to a new subsidiary that aligns with Amarantus' holding company business model.
Aloha
https://www.amarantus.com/news/press-releases...ate-update
GC has been delivering and hasn't changed or updated the timeframe...
1) Elto Pharma
2) MANF Therapeutic
3) Amarantus intends to assign these diagnostic assets to a new subsidiary that aligns with Amarantus' holding company business model.
Aloha
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)